<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01143168</url>
  </required_header>
  <id_info>
    <org_study_id>Cellonis-CR-1.3</org_study_id>
    <nct_id>NCT01143168</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy for Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Pilot Study on Transplantation Therapy Using Autologous Bone Marrow Mononuclear Cells and Umbilical Cord Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellonis Biotechnology Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cellonis Biotechnology Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility, efficacy and safety of
      transplantation therapy using bone marrow mononuclear cells and umbilical cord mesenchymal
      stem cells for patients with type 1 diabetes mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the feasibility, safety and efficacy of transplantation using autologous bone
      marrow mononuclear cells and umbilical cord mesenchymal stem cells in patients with type 1
      diabetes mellitus.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of reducing exogenous insulin requirement; Hemoglobin A1c; Fast blood glucose (FBG) and postmeal blood glucose (PBG); C-peptide levels.</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of reducing exogenous insulin requirement compared with baseline. Hemoglobin A1c. Fast blood glucose (FBG) and postmeal blood glucose (PBG). C-peptide levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious adverse event frequency and severity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells</intervention_name>
    <description>First Transplantation: after finishing all required examines according to protocol on Day 0, ABM-MNCs + UCMSCs are transplanted through pancreas artery percutaneously; Second Transplantation: after finishing all required examines on Day 7±1, BM-MNCs UCMSCs are transplanted intravenously; Third Transplantation: after finishing all required examines on Day 14±2, BM-MNCs + UCMSCs are transplanted intravenously.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Free will taking part in the study and ability to provide written informed consent.

          2. Confirmed diagnosis of type I diabetes for at least 2 years

          3. Insulin-dependent.

          4. Age 18-50 years, Male/Female.

          5. FBG≥7.0 mmol/L, and HbAc1≥7％.

          6. Not pregnant or nursing.

          7. Negative pregnancy test.

          8. Fertile patients will use effective contraception.

        Exclusion Criteria:

          1. Presence of acute diabetic complications in the acute stage as recent myocardial
             infarction, recent cerebral vascular accident (CVA) or acute renal failure.

          2. Severe concurrent medical condition (e.g. lung disease, or hematopoietic dysfunction,
             or liver dysfunction).

          3. Active infection requiring treatment.

          4. Known immunosuppressive disease, e.g. HIV infection, or hepatitis B or C infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shi X Y, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Armed Police General Hospital, P. R. China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Armed Police General Hospital, P. R. China</name>
      <address>
        <city>Beijing</city>
        <zip>100085</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2010</study_first_posted>
  <last_update_submitted>June 11, 2010</last_update_submitted>
  <last_update_submitted_qc>June 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Cellonis Biotechnology Co. Ltd.</name_title>
    <organization>Others</organization>
  </responsible_party>
  <keyword>stem cells;</keyword>
  <keyword>diabetes mellitus;</keyword>
  <keyword>treatment.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

